Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381342 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Exenatide as Monotherapy
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
NCT00381342: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00381342 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 233 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00381342, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
Study Summary
This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.
Primary Outcome
Change in HbA1c from Baseline to Week 24
Interventions
- DRUG placebo
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
What the finished NCT00381342 record still lists
NCT00381342 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00381342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00381342 about?
NCT00381342 is a clinical study titled "Safety and Efficacy of Exenatide as Monotherapy". This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.
What is the current status of trial NCT00381342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2006-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00381342?
The interventions under investigation include: placebo (DRUG), exenatide (DRUG).
Who is sponsoring clinical trial NCT00381342?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00381342's enrollment target sits among peer trials
233 1298th of 2000 higher than 703 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia